Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer
European Journal of Cancer · 2025-10 · 228 · 115739
DOI: 10.1016/j.ejca.2025.115739 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Cancer, 2025-10. Verfasst von Carmine Valenza und 1 weiteren Autor:innen. Beteiligte Einrichtung: European Institute of Oncology, IRCCS, Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy. Hauptthemen laut MEDLINE: Breast Neoplasms, Estrogen Receptor alpha, Selective Estrogen Receptor Modulators. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: American-Italian Cancer Foundation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- European Institute of Oncology, IRCCS, Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.
- European Institute of Oncology, IRCCS, Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy. Electronic address: giuseppe.curigliano@ieo.it.
Förderung
- American-Italian Cancer Foundation
Zitieren
APA
Valenza, C., & Curigliano, G. (2025). Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer. European Journal of Cancer, 228, 115739. https://doi.org/10.1016/j.ejca.2025.115739
Vancouver
Valenza C, Curigliano G. Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer. European Journal of Cancer. 2025;228:115739. doi:10.1016/j.ejca.2025.115739
BibTeX
@article{Valenza2025,
author = {Valenza, Carmine and Curigliano, Giuseppe},
title = {Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer},
journal = {European Journal of Cancer},
year = {2025},
volume = {228},
pages = {115739},
doi = {10.1016/j.ejca.2025.115739}
}
EUVIMED